| Literature DB >> 22982770 |
Chun Li1, Bo Liu, Jonathan Chang, Todd Groessl, Matthew Zimmerman, You-Qun He, John Isbell, Tove Tuntland.
Abstract
Successful drug discovery relies on the selection of drug candidates with good in vivo pharmacokinetic (PK) properties as well as appropriate preclinical efficacy and safety profiles. In vivo PK profiling is often a bottleneck in the discovery process. In this review, we focus on the tiered in vivo PK approaches implemented at the Genomics Institute of the Novartis Research Foundation (GNF), which includes snapshot PK, rapid PK and full PK studies. These in vivo PK approaches are well integrated within discovery research, allow tremendous flexibility and are highly efficient in supporting the diverse needs and increasing demand for in vivo profiling. The tiered in vivo PK studies expedite compound profiling and help guide the selection of more desirable compounds into efficacy models and for progression into development.Mesh:
Substances:
Year: 2012 PMID: 22982770 DOI: 10.1016/j.drudis.2012.09.004
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851